Palau Majesty Development Inc. was established in 2016 as a development company focused on constructing the Sheraton Palau Resort. However, due to issues with the parent company of the project, the business was temporarily suspended, and shares were transferred to Makoto Noborisaka, the architect responsible for the hotel’s design.

The company remained dormant within Palau until late 2023, when a project team led by Fumihisa Kojima filed for reinstatement with the Foreign Investment Board (FIB) of the Republic of Palau. As a result, in November 2024, the company regained its operational status with the necessary permits for hotel construction still intact.

Makoto Noborisaka is a board member of Palau Majesty Development Inc. and the CEO of Blue Ocean Design Inc. With over 20 years of experience in urban planning and landscape design, he has been involved in more than 50 major projects, including Tokyo Station’s Yaesu Plaza, Tokyo Midtown Plaza, and Osaka Dome City. In 2015, he founded Blue Ocean Design, leveraging two decades of experience at a major Japanese architectural firm. Currently, he leads numerous development projects across Asia and will oversee almost all construction initiatives for this project. His expertise includes landscape design, urban planning and design, and architecture.

Fumihisa Kojima is a board member of Palau Majesty Development Inc., CEO of Studio Makyu Co.,Ltd. and Biozipcode, Inc., and CTO of KIYAN MEDICAL Co., Ltd. He is also recognized as a pioneer in supercomputer development and fintech. His diverse achievements include conducting workshops and assisting investigations for the Aichi Prefectural Police in Japan, giving seminars for the Japan Blockchain Association (BCCC), and presenting at the Japan Cryptoasset Business Association (JCBA).

Through Biozipcode, Inc., he collaborates with Professor Hideto Kojima of Shiga University of Medical Science to develop treatments aimed at curing diabetes and advancing the cell-targeting technology “Biozipcode.” He also partners with pharmaceutical companies and other organizations to pursue this mission.

It is important to note that our company has no affiliation with organizations that have previously solicited high-yield investments through cryptocurrency AI trading.